Rectal Neuroendocrine Tumor

3

Review clinical trials related to Rectal Neuroendocrine Tumor. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Underwater Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Small Rectal Neuroendocrine Tumors

Underwater endoscopic mucosal resection (UEMR) and endoscopic submucosal dissection (ESD) have both been reported to be two effective treatment methods for small rectal neuroendocrine tumor (NET). However, there is no consensus on the best method for the endoscopic resection of rectal NET. Therefore, we aimed to compare the efficacy and safety of UEMR and ESD for the treatment of small rectal NET.

Participants needed: 174
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Nanfang Hospital, Southern Medical UniversityUpdated: Aug 12, 2026Locations: 1
Eligibility criteria

Age from 18 to 75 years; [+3]

Unable to tolerate ESD or UEMR as assessed by the research team; [+6]

Status: Not yet recruiting

Endoscopic Resection for Small Rectal Neuroendocrine Tumors

According to clinical practice and relevant retrospective research data, both modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic mucosal resection with a ligation device(ESMR-L) were reported to be effective for the treatment of small rectal neuroendocrine tumors (NETs) . However, there is a lack of multicenter prospective studies to evaluate the advantages and disadvantages of mEMR-C and mEMR-L. mEMR-C is the modified ESMR-L without submucosal injection.

Participants needed: 120
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Guangdong Provincial People's HospitalUpdated: Mar 30, 2025
Eligibility criteria

Age from 18 to 80 years; [+3]

Unable to tolerate mEMR-L or mEMR-C as assessed by the research team of each cen... [+6]

Status: Not yet recruiting

Endoscopic Resection for Small Rectal Neuroendocrine Tumors

In previous single center study, both modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic submucosal dissection (ESD) were reported to be effective for the treatment of small rectal neuroendocrine tumors (NETs) and mEMR-C was inferior to ESD for the treatment of small rectal NETs (≤10 mm), as it has shorter operation times and lower hospitalization costs. However, a multicenter randomized controlled trial is needed to prove the universality and generality of these findings.

Participants needed: 102
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Nanfang Hospital, Southern Medical UniversityUpdated: Jul 1, 2022
Eligibility criteria

Age from 18 to 75 years; [+3]

Unable to tolerate ESD or MEMR-C as assessed by the research team of each center... [+6]